BRPI0913889A2 - uso de nifurtimox e composição compreendendo o referido composto para o combate da giardiose - Google Patents

uso de nifurtimox e composição compreendendo o referido composto para o combate da giardiose

Info

Publication number
BRPI0913889A2
BRPI0913889A2 BRPI0913889A BRPI0913889A BRPI0913889A2 BR PI0913889 A2 BRPI0913889 A2 BR PI0913889A2 BR PI0913889 A BRPI0913889 A BR PI0913889A BR PI0913889 A BRPI0913889 A BR PI0913889A BR PI0913889 A2 BRPI0913889 A2 BR PI0913889A2
Authority
BR
Brazil
Prior art keywords
giargiosis
nifurtimox
combating
compound
composition
Prior art date
Application number
BRPI0913889A
Other languages
English (en)
Inventor
Achim Harder
Eva-Maria Kruedewagen
Gabriele Petry
Gisela Grief
Thomas Bach
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BRPI0913889A2 publication Critical patent/BRPI0913889A2/pt
Publication of BRPI0913889B1 publication Critical patent/BRPI0913889B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
BRPI0913889A 2008-07-02 2009-06-20 uso de nifurtimox e composição compreendendo o referido composto para o combate da giardiose BRPI0913889B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008031284A DE102008031284A1 (de) 2008-07-02 2008-07-02 Neue Bekämpfungsmöglichkeit der Giardiose
PCT/EP2009/004475 WO2010000399A1 (de) 2008-07-02 2009-06-20 Verwendung von nifurtimox zur behandlung der giardiose

Publications (2)

Publication Number Publication Date
BRPI0913889A2 true BRPI0913889A2 (pt) 2015-10-27
BRPI0913889B1 BRPI0913889B1 (pt) 2019-02-05

Family

ID=41077987

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913889A BRPI0913889B1 (pt) 2008-07-02 2009-06-20 uso de nifurtimox e composição compreendendo o referido composto para o combate da giardiose

Country Status (29)

Country Link
US (1) US8440612B2 (pt)
EP (1) EP2310018B1 (pt)
JP (1) JP5627579B2 (pt)
KR (1) KR101720805B1 (pt)
CN (1) CN102083441B (pt)
AR (1) AR072425A1 (pt)
AU (1) AU2009266125B2 (pt)
BR (1) BRPI0913889B1 (pt)
CA (1) CA2729730C (pt)
CL (2) CL2010001577A1 (pt)
CO (1) CO6321270A2 (pt)
CR (1) CR20110022A (pt)
DE (1) DE102008031284A1 (pt)
DK (1) DK2310018T3 (pt)
DO (1) DOP2010000405A (pt)
EC (1) ECSP10010720A (pt)
ES (1) ES2444581T3 (pt)
IL (1) IL209698A (pt)
MX (1) MX2010014446A (pt)
MY (1) MY157007A (pt)
NI (1) NI201100008A (pt)
NZ (1) NZ590276A (pt)
PE (1) PE20110283A1 (pt)
PL (1) PL2310018T3 (pt)
RU (1) RU2538713C9 (pt)
SV (1) SV2011003785A (pt)
UA (1) UA103328C2 (pt)
WO (1) WO2010000399A1 (pt)
ZA (1) ZA201009225B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2814694C (en) * 2010-10-12 2019-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating giardiasis
CN107835818B (zh) 2015-05-20 2022-04-29 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
KR20220003663A (ko) 2015-12-28 2022-01-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 뎁시펩티드 화합물
EP3541789A1 (en) 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
EP3750527A1 (en) * 2019-06-13 2020-12-16 Bayer AG Stable tablet formulation of nifurtimox and process for producing the same
CN114377018B (zh) * 2020-10-21 2024-02-06 中国医学科学院药物研究所 硝呋莫司在制备抗流感病毒药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1170957B (de) * 1962-11-23 1964-05-27 Bayer Ag Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten
JPH081908B2 (ja) * 1987-07-22 1996-01-10 三菱電機株式会社 超格子半導体素子
NO176766C (no) * 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
CA2132199C (en) 1992-03-17 2000-01-18 Hitoshi Nishiyama Depsipeptide derivative, production thereof and use thereof
DE4317458A1 (de) 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
CN1073560C (zh) 1993-02-19 2001-10-24 明治制果株式会社 环缩酚酸肽pf1022衍生物
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317457A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
US5646244A (en) 1993-09-06 1997-07-08 Fujisawa Pharmaceutical Co., Ltd. Cyclodepsipeptide compound
DE4401389A1 (de) 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
CN1071323C (zh) * 1995-06-30 2001-09-19 藤泽药品工业株式会社 缩肽衍生物或其盐的制造方法
NZ318515A (en) 1995-09-22 2000-05-26 Bayer Ag Cyclodepsipeptide PF1022 derivatives and compositions thereof
DE19545639A1 (de) 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5874630A (en) * 1998-01-06 1999-02-23 Occidental Chemical Corporation Synthesis of mercaptans from alcohols
US6133228A (en) * 1998-05-28 2000-10-17 Firmenich Sa Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters
DE19828047A1 (de) * 1998-06-24 1999-12-30 Bayer Ag Substituierte Cyclooctadepsipeptide
ZA200704784B (en) * 2004-11-12 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
DE102005033496A1 (de) 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel

Also Published As

Publication number Publication date
CO6321270A2 (es) 2011-09-20
DK2310018T3 (da) 2014-03-24
US8440612B2 (en) 2013-05-14
CA2729730A1 (en) 2010-01-07
IL209698A (en) 2016-03-31
AU2009266125B2 (en) 2015-06-04
JP5627579B2 (ja) 2014-11-19
CN102083441A (zh) 2011-06-01
ECSP10010720A (es) 2011-01-31
CR20110022A (es) 2011-05-10
ZA201009225B (en) 2012-03-28
EP2310018A1 (de) 2011-04-20
BRPI0913889B1 (pt) 2019-02-05
NI201100008A (es) 2011-08-10
JP2011526265A (ja) 2011-10-06
CN102083441B (zh) 2013-07-24
CL2010001577A1 (es) 2011-05-06
PL2310018T3 (pl) 2014-05-30
AU2009266125A1 (en) 2010-01-07
MY157007A (en) 2016-04-15
PE20110283A1 (es) 2011-05-07
RU2011103475A (ru) 2012-08-10
RU2538713C2 (ru) 2015-01-10
CA2729730C (en) 2016-03-22
DOP2010000405A (es) 2011-01-15
MX2010014446A (es) 2011-02-22
AR072425A1 (es) 2010-08-25
EP2310018B1 (de) 2013-12-18
CL2013000709A1 (es) 2013-08-23
UA103328C2 (uk) 2013-10-10
KR20110031357A (ko) 2011-03-25
ES2444581T3 (es) 2014-02-25
DE102008031284A1 (de) 2010-01-07
IL209698A0 (en) 2011-02-28
HK1158113A1 (en) 2012-07-13
US20110105388A1 (en) 2011-05-05
KR101720805B1 (ko) 2017-03-28
RU2538713C9 (ru) 2015-08-20
NZ590276A (en) 2012-12-21
WO2010000399A1 (de) 2010-01-07
SV2011003785A (es) 2011-05-20

Similar Documents

Publication Publication Date Title
BRPI0918359A2 (pt) composto, composição agroquímica, uso da composição agroquímica e método para preparação do composto
PT2124638T (pt) Composição de aperfeiçoamento de desempenho e utilização da mesma
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0817200A2 (pt) composições oftálmicas sólida e uso de compostos para fabricação de medicamento
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0907365A2 (pt) Composição antimicrobiana e uso
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0914069A2 (pt) composição de vacina para uso contra o influenza
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0821327A2 (pt) Derivado de catecol, composição farmacêutica contendo o mesmo, uso do derivado de catecol, e uso da composição farmacêutica
PT2498752T (pt) Composição para aplicação tópica, usos da mesma, dispositivo aplicador e kit de peças
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2009, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2624 DE 20-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.